Business Standard

Piramal Healthcare gets EU nod for orthopaedic product

Press Trust of India  |  New Delhi 

part of Piramal group today said it has received approval from European regulator to market its bio-orthopaedic product BST- used for cartilage repair in the European Union.

"The current European approval provides access to a $200 million-market in Europe with a potential for a larger market with greater penetration of treatment in Europe," Piramal Group Chairman said.

The approval will serve as the basis to obtain commercial authorisation for the product in other geographic areas such West Asia, Asia Pacific region, South America and other countries including India, said in a filing to

"The company plans to launch the BST-for commercial sale in the fourth quarter of the 2012 calendar year after completing user studies with key opinion leaders," it added.

had acquired assets relating to BST-from Canada based BioSyntech Technologies Inc in 2010, the company said.

BST-is a European Union class III medical device, said.



Scrips of were today trading at Rs 453 per share in the afternoon trade on BSE, down 1.01% from its previous close.

 

RECOMMENDED FOR YOU

Piramal Healthcare gets EU nod for orthopaedic product

Piramal Healthcare part of Piramal group today said it has received approval from European regulator to market its bio-orthopaedic product BST- CarGel used for cartilage repair in the European Union.

part of Piramal group today said it has received approval from European regulator to market its bio-orthopaedic product BST- used for cartilage repair in the European Union.

"The current European approval provides access to a $200 million-market in Europe with a potential for a larger market with greater penetration of treatment in Europe," Piramal Group Chairman said.

The approval will serve as the basis to obtain commercial authorisation for the product in other geographic areas such West Asia, Asia Pacific region, South America and other countries including India, said in a filing to

"The company plans to launch the BST-for commercial sale in the fourth quarter of the 2012 calendar year after completing user studies with key opinion leaders," it added.

had acquired assets relating to BST-from Canada based BioSyntech Technologies Inc in 2010, the company said.

BST-is a European Union class III medical device, said.

Scrips of were today trading at Rs 453 per share in the afternoon trade on BSE, down 1.01% from its previous close.

 

image
Business Standard
177 22

Piramal Healthcare gets EU nod for orthopaedic product

part of Piramal group today said it has received approval from European regulator to market its bio-orthopaedic product BST- used for cartilage repair in the European Union.

"The current European approval provides access to a $200 million-market in Europe with a potential for a larger market with greater penetration of treatment in Europe," Piramal Group Chairman said.

The approval will serve as the basis to obtain commercial authorisation for the product in other geographic areas such West Asia, Asia Pacific region, South America and other countries including India, said in a filing to

"The company plans to launch the BST-for commercial sale in the fourth quarter of the 2012 calendar year after completing user studies with key opinion leaders," it added.

had acquired assets relating to BST-from Canada based BioSyntech Technologies Inc in 2010, the company said.

BST-is a European Union class III medical device, said.

Scrips of were today trading at Rs 453 per share in the afternoon trade on BSE, down 1.01% from its previous close.

 

image
Business Standard
177 22